mProX™ Human IKBKB Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1169	Magic™ Human IKK-beta in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

IKBKB

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Immunology Research

Related Diseases

Immunodeficiency 15A and Immunodeficiency 15B. Among its related pathways are MyD88 dependent cascade initiated on endosome and TNFR1 Pathway

Gene ID

3551

UniProt ID

O14920

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

The protein IKK-β, sometimes referred to as inhibitor of nuclear factor kappa-B kinase subunit beta, is encoded by the IKBKB gene in humans. IKK-β is an enzyme that functions as a protein subunit of IκB kinase, a part of the intracellular signaling pathway that is activated by cytokines and responsible for inducing immunological responses. Nuclear Transcription factor kappa-B, or NF-κB, is a transcription factor that is activated by IKK activity. The protein known as the inhibitor of NF-κB, or IκBα, is phosphorylated by activated IKK-β and binds to NF-κB to prevent it from functioning. The ubiquitination pathway breaks down phosphorylated IκB, releasing NF-κB and enabling its entry into the cell nucleus, where it activates several genes linked to inflammation and other immune responses. The customized IKBKB stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat William

The IKBKB KO cell line worked as advertised and was a cost-effective alternative in our studies. Apr 08 2022

chat Verified Customer

chat Jessica

The IKBKB cell line worked flawlessly, and the detailed protocols provided by the company made the whole process much easier. Aug 10 2022

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 pS13 HTT levels are regulated by inhibitor of IKBKB and okadaic acid-sensitive phosphatases.

HEK293T cells overexpressing N571 Q55 HTT were treated with okadaic acid (OA), either in the presence or absence of IKBKB or its kinase-dead mutant IKBKB KD. When IKBKB is overexpressed in conjunction with OA therapy, Western blotting demonstrates significantly elevated pS13 HTT levels and enhanced auto-phosphorylation of IKBKB at residues S177/S181. However, IKBKB KD overexpression is not observed.

Ref: Cariulo, Cristina, et al. "IKBKB reduces huntingtin aggregation by phosphorylating serine 13 via a non-canonical IKK pathway." Life Science Alliance 6.10 (2023).

Pubmed: 37553253

DOI: 10.26508/lsa.202302006

Research Highlights

Through downregulating IKBKB, miR-200b, a transcriptional target of NF-κB, inhibits the proliferation and migration of breast cancer cells as well as NF-κB activation. This suggests that miR-200b may have use in breast cancer patients as a therapeutic target.
Wu, Hewen, et al. "A negative feedback loop between miR-200b and the nuclear factor-κB pathway via IKBKB/IKK-β in breast cancer cells." The FEBS journal 283.12 (2016): 2259-2271.
Pubmed: 26433127 DOI: 10.1111/febs.13543

This missense mutation results in very similar cellular and metabolic abnormalities in humans and mice. Precise rodent models created with CRISPR/Cas9 can provide information on pathogenesis and aid in the characterization of new syndromes resulting from de novo germline mutations.
Cardinez, Chelisa, et al. "Gain-of-function IKBKB mutation causes human combined immune deficiency." Journal of Experimental Medicine 215.11 (2018): 2715-2724.
Pubmed: 30337470 DOI: 10.1084/jem.20180639